Towards a nanospecific approach for risk assessment.

In the current paper, a new strategy for risk assessment of nanomaterials is described, which builds upon previous project outcomes and is developed within the FP7 NANoREG project. NANoREG has the aim to develop, for the long term, new testing strategies adapted to a high number of nanomaterials where many factors can affect their environmental and health impact. In the proposed risk assessment strategy, approaches for (Quantitative) Structure Activity Relationships ((Q)SARs), grouping and read-across are integrated and expanded to guide the user how to prioritise those nanomaterial applications that may lead to high risks for human health. Furthermore, those aspects of exposure, kinetics and hazard assessment that are most likely to be influenced by the nanospecific properties of the material under assessment are identified. These aspects are summarised in six elements, which play a key role in the strategy: exposure potential, dissolution, nanomaterial transformation, accumulation, genotoxicity and immunotoxicity. With the current approach it is possible to identify those situations where the use of nanospecific grouping, read-across and (Q)SAR tools is likely to become feasible in the future, and to point towards the generation of the type of data that is needed for scientific justification, which may lead to regulatory acceptance of nanospecific applications of these tools.

[1]  Warren H. Finlay,et al.  Particle deposition in the respiratory tract , 2019, The Mechanics of Inhaled Pharmaceutical Aerosols.

[2]  A. Burls Critical appraisal , 2016, Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists.

[3]  Ana Proykova,et al.  Scientific Committee on Emerging and Newly Identified Health Risks SCENIHR Opinion on the Guidance on the Determination of Potential Health Effects of Nanomaterials Used in Medical Devices , 2015 .

[4]  Ken Donaldson,et al.  Possible genotoxic mechanisms of nanoparticles: Criteria for improved test strategies , 2010, Nanotoxicology.

[5]  Craig A. Poland,et al.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma , 2010, Particle and Fibre Toxicology.

[6]  Reinhard Kreiling,et al.  A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). , 2015, Regulatory toxicology and pharmacology : RTP.

[7]  Gibson Peter,et al.  Towards a review of the EC Recommendation for a definition of the term "nanomaterial": Part 3: Scientific-technical evaluation of options to clarify the definition and to facilitate its implementation , 2015 .

[8]  P. Hoet,et al.  Nanoparticles – known and unknown health risks , 2004, Journal of nanobiotechnology.

[9]  Andreas Luch,et al.  A redox proteomics approach to investigate the mode of action of nanomaterials. , 2016, Toxicology and applied pharmacology.

[10]  Xiang Wang,et al.  Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. , 2013, Accounts of chemical research.

[11]  Gibson Peter,et al.  Towards a review of the EC Recommendation for a definition of the term "nanomaterial"; Part 1: Compilation of information concerning the experience with the definition , 2014 .

[12]  Maria João Silva,et al.  Role of Nanogenotoxicology Studies in Safety Evaluation of Nanomaterials , 2015 .

[13]  Gibson Peter,et al.  Towards a review of the EC Recommendation for a definition of the term "nanomaterial"Part 2: Assessment of collected information concerning the experience with the defintion , 2014 .

[14]  R. Tice,et al.  Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing , 2000, Environmental and molecular mutagenesis.

[15]  Rui Chen,et al.  Beyond PM2.5: The role of ultrafine particles on adverse health effects of air pollution. , 2016, Biochimica et biophysica acta.

[16]  Eleonore Fröhlich,et al.  Cellular targets and mechanisms in the cytotoxic action of non-biodegradable engineered nanoparticles. , 2013, Current drug metabolism.

[17]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[18]  A. Collins,et al.  The comet assay for DNA damage and repair , 2004, Molecular biotechnology.

[19]  Peter Wick,et al.  Engineered nanomaterial uptake and tissue distribution: from cell to organism , 2013, International journal of nanomedicine.

[20]  Jingwen Chen,et al.  A practical approach to determine dose metrics for nanomaterials , 2015, Environmental toxicology and chemistry.

[21]  Dhimiter Bello,et al.  Mapping the biological oxidative damage of engineered nanomaterials. , 2013, Small.

[22]  Jim E Riviere,et al.  A physiologically based pharmacokinetic model for polyethylene glycol-coated gold nanoparticles of different sizes in adult mice , 2015, Nanotoxicology.

[23]  Marina A Dobrovolskaia,et al.  Evaluation of nanoparticle immunotoxicity. , 2009, Nature nanotechnology.

[24]  G. Oberdörster,et al.  Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.

[25]  Lang Tran,et al.  ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy , 2014, Particle and Fibre Toxicology.

[26]  Marina A Dobrovolskaia,et al.  Current understanding of interactions between nanoparticles and the immune system. , 2016, Toxicology and applied pharmacology.

[27]  Henriqueta Louro,et al.  Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells , 2005, Environmental and molecular mutagenesis.

[28]  Julie Laloy,et al.  Suitability of analytical methods to measure solubility for the purpose of nanoregulation , 2015, Nanotoxicology.

[29]  Paul L. Carmichael,et al.  Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs , 2011, Mutagenesis.

[30]  Min Chen,et al.  Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. , 2005, Experimental cell research.

[31]  Antonio Marcomini,et al.  Supporting decision-making for sustainable nanotechnology , 2015, Environment Systems and Decisions.

[32]  M. Marinovich,et al.  Risk Assessment of Products of Nanotechnologies , 2009 .

[33]  J. Powell,et al.  Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. , 2010, Journal of autoimmunity.

[34]  Lang Tran,et al.  Safe handling of nanotechnology , 2006, Nature.

[35]  Teresa F. Fernandes,et al.  The MARINA Risk Assessment Strategy: A Flexible Strategy for Efficient Information Collection and Risk Assessment of Nanomaterials , 2015, International journal of environmental research and public health.

[36]  Kimberly F. Sellers,et al.  Grouping nanomaterials : A strategy towards grouping and read-across , 2015 .

[37]  Jim E Riviere,et al.  Pharmacokinetics of metallic nanoparticles. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[38]  Hugh J. Byrne,et al.  Concern-driven integrated approaches to nanomaterial testing and assessment – report of the NanoSafety Cluster Working Group 10 , 2013, Nanotoxicology.

[39]  Reinhard Kreiling,et al.  A critical appraisal of existing concepts for the grouping of nanomaterials. , 2014, Regulatory toxicology and pharmacology : RTP.

[40]  Steffen Loft,et al.  Nanomaterial translocation–the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs–a review , 2015, Critical reviews in toxicology.

[41]  M. Fenech The in vitro micronucleus technique. , 2000, Mutation research.

[42]  Craig A. Poland,et al.  Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Antonio Marcomini,et al.  Grouping and Read-Across Approaches for Risk Assessment of Nanomaterials , 2015, International journal of environmental research and public health.

[44]  S. Doak,et al.  NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. , 2009, Biomaterials.

[45]  W. D. de Jong,et al.  Novel insights into the risk assessment of the nanomaterial synthetic amorphous silica, additive E551, in food , 2015, Nanotoxicology.

[46]  F. Goñi-de-Cerio,et al.  Nanoparticles and blood-brain barrier: the key to central nervous system diseases. , 2014, Journal of nanoscience and nanotechnology.

[47]  Jeroen Lammertyn,et al.  Semi-automatic size measurement of primary particles in aggregated nanomaterials by transmission electron microscopy , 2014 .

[48]  Reinhard Kreiling,et al.  Case studies putting the decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping) into practice. , 2016, Regulatory toxicology and pharmacology : RTP.

[49]  Claudia Röhl,et al.  Manufactured nanomaterials: categorization and approaches to hazard assessment , 2014, Archives of Toxicology.

[50]  I Pastan Cell transformation. , 1979, Methods in enzymology.

[51]  Konrad Hungerbühler,et al.  A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles , 2013, International journal of nanomedicine.

[52]  Gibson Peter,et al.  Requirements on measurements for the implementation of the European Commission definition of the term 'nanomaterial' , 2012 .

[53]  Lutz Mädler,et al.  Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. , 2012, ACS nano.

[54]  Wijnhoven Swp,et al.  Exposure to nanomaterials in consumer products , 2009 .

[55]  Manuela Semmler-Behnke,et al.  Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration , 2011, Nanotoxicology.

[56]  Craig A. Poland,et al.  Nanotoxicity: challenging the myth of nano-specific toxicity. , 2013, Current opinion in biotechnology.

[57]  Karen L Wooley,et al.  Cytokines as biomarkers of nanoparticle immunotoxicity. , 2013, Chemical Society reviews.